share_log

Top 5 Health Care Stocks That May Explode In July

Top 5 Health Care Stocks That May Explode In July

7月可能會爆發的前5個醫療保健股票
Benzinga ·  07/08 20:40

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

醫療保健板塊中最超賣的股票爲買入被低估的公司提供了機會。

The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down. When compared to a stock's price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the RSI is below 30, according to Benzinga Pro.

RSI指標是一種動量指標，它比較了股票在價格上漲時的強度與在價格下跌時的強度。與股票的價格走勢進行比較，可以給交易者更好的了解股票短期內表現的良好程度。當RSI低於30時，資產通常被認爲是超賣的，根據Benzinga Pro的數據。

Here's the latest list of major oversold players in this sector, having an RSI near or below 30.

以下是本行業板塊最近的主要超賣股票列表，RSI接近或低於30。

Cassava Sciences Inc (NASDAQ:SAVA)

Cassava Sciences股份有限公司（納斯達克股票代碼：SAVA）

  • On July 1, Cassava Sciences engaged the U.S. Department of Justice (DOJ) and the U.S. Securities and Exchange Commission (SEC) amid ongoing investigations into the company and two senior employees. The company's stock fell around 46% over the past five days and has a 52-week low of $8.79.
  • RSI Value: 14.66
  • SAVA Price Action: Shares of Cassava Sciences fell 5.2% to close at $10.22 on Friday.
  • Benzinga Pro's real-time newsfeed alerted to latest Cassava Sciences news.
  • 7月1日，Cassava Sciences在調查公司以及兩名高管的持續調查中，向美國司法部和美國證券交易委員會尋求援助。公司股價在過去5天內下跌了大約46％，52周最低點爲8.79美元。
  • RSI值：14.66
  • SAVA股票行情：週五，Cassava Sciences股票下跌5.2％，收於10.22美元。
  • Benzinga Pro實時新聞提醒了最新的Cassava Sciences新聞。

Owens & Minor, Inc. (NYSE:OMI)

歐文斯與少數股東有限公司（紐交所股票代碼：OMI）

  • On June 24, Owens & Minor named Jonathan A. Leon as interim CFO. The company's stock fell around 26% over the past month. It has a 52-week low of $12.47.
  • RSI Value: 15.74
  • OMI Price Action: Shares of Owens & Minor fell 4% to close at $12.59 on Friday.
  • Benzinga Pro's charting tool helped identify the trend in Owens & Minor stock.
  • 6月24日，Owens＆Minor任命Jonathan A. Leon擔任臨時首席財務官。公司股價在過去一個月內下跌了大約26％，52周最低點爲12.47美元。
  • RSI值：15.74
  • OMI股票行情：週五，Owens＆Minor股票下跌了4％，收於12.59美元。
  • Benzinga Pro的圖表工具有助於識別Owens＆Minor股票的趨勢。

Castle Biosciences Inc (NASDAQ:CSTL)

Castle Biosciences Inc（納斯達克股票代碼：CSTL）

  • On July 5, Baird analyst Catherine Ramsey maintained Castle Biosciences with an Outperform and maintained a $34 price target. The company's stock fell around 25% over the past month and has a 52-week low of $12.07.
  • RSI Value: 17.90
  • CSTL Price Action: Shares of Castle Biosciences fell 18.1% to close at $17.40 on Friday.
  • Benzinga Pro's signals feature notified of a potential breakout in CSTL's shares.
  • 7月5日，Baird分析師Catherine Ramsey維持對Castle Biosciences的評級爲優於市場，並維持34美元的目標價。公司股價在過去一個月內下跌了大約25％，52周最低點爲12.07美元。
  • RSI值：17.90
  • CSTL股票行情：週五，Castle Biosciences股票下跌了18.1％，收於17.40美元。
  • Benzinga Pro的信號功能通知了CSTL股票的潛在突破。

National Research Corporation (NASDAQ:NRC)

National Research Corporation（納斯達克股票代碼：NRC）

  • On May 7, National Research posted a decline in quarterly sales results. Michael Hays, Chief Executive Officer, commented, "NRC continues to be strongly positioned for growth in our expanding markets. Our decades of benchmarks and trusted thought leadership afford healthcare insights unavailable to most competitors, while our client service remains unmatched, and we continue to roll out innovative new products and technologies." The company's shares lost around 10% over the past month. The company's 52-week low is $21.73.
  • RSI Value: 19.72
  • NRC Price Action: Shares of National Research gained 0.2% to close at $22.99 on Friday.
  • Benzinga Pro's earnings calendar was used to track National Research's upcoming earnings report.
  • 5月7日，National Research公佈了季度銷售業績下降的結果。首席執行官Michael Hays評論說：“NRC繼續在不斷擴大的市場中強勁地實現增長。我們幾十年的基準和可信的思想領導爲大多數競爭對手無法獲得的醫療洞見提供了支持，同時我們的客戶服務無與倫比，並繼續推出創新的新產品和技術。”公司股票在過去一個月內下跌了約10％。該公司的52周最低點爲21.73美元。
  • RSI值：19.72
  • NRC股票行情：週五，National Research的股票上漲了0.2％，收於22.99美元。
  • Benzinga Pro的業績日曆用於跟蹤National Research即將發佈的業績。

Pacira Biosciences Inc (NASDAQ:PCRX)

pacira biosciences股份有限公司（納斯達克股票代碼：PCRX）

  • On July 2, Pacira BioSciences said the FDA approved a generic version of Exparel. The company's shares fell around 25% over the past five days. The company has a 52-week low of $20.52.
  • RSI Value: 21.16
  • PCRX Price Action: Shares of Pacira Biosciences fell 2.8% to close at $21.06 on Friday.
  • Insider trades for Pacira Biosciences were monitored using Benzinga Pro.
  • 7月2日，pacira biosciences公司表示FDA批准了Exparel的仿製版本。在過去的五天中，該公司的股票下跌了約25%。該公司的52周低點爲20.52美元。
  • RSI指數值: 21.16
  • PCRX價值操作: pacira biosciences股份有限公司的股票週五下跌2.8%，收於21.06美元。
  • 使用Benzinga Pro監控pacira biosciences公司的內部交易。

Read More: Top 3 Financial Stocks You'll Regret Missing In Q3

閱讀更多：你會後悔在第三季度錯失這三家金融股。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論